<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01920906</url>
  </required_header>
  <id_info>
    <org_study_id>JWK-0816</org_study_id>
    <nct_id>NCT01920906</nct_id>
  </id_info>
  <brief_title>Comparative Analysis of Small and Large Plaque Psoriasis</brief_title>
  <official_title>Comparative Analysis of Small and Large Plaque Psoriasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rockefeller University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rockefeller University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Psoriasis is a chronic, debilitating skin disorder with an estimated prevalence of 2%.&#xD;
      Psoriatic skin lesions start with initial pinhead-sized macules and then coalesce into&#xD;
      plaques of varying sizes. Despite the great strides in the studies for psoriasis, it is still&#xD;
      unclear why psoriatic skin lesions start with small macules and then spread peripherally.&#xD;
&#xD;
      To study peripheral spreading of psoriasis, investigators plan to study small plaque&#xD;
      psoriasis in comparison to large plaque psoriasis in the Korean population. Large plaque&#xD;
      psoriasis is the most common form of psoriasis, seen in approximately 90% of all psoriasis&#xD;
      participants. Large psoriatic plaques are &gt;5 cm in size and localize to the extensor aspects&#xD;
      of the elbows, knees, scalp, and genital area. On the other hand, small plaque psoriasis is&#xD;
      the common or typical form of psoriasis that occurs particularly in Korea and other Asian&#xD;
      countries. Korean small plaque psoriasis, even when chronic, remains &lt;2 cm in size and is&#xD;
      widely distributed on the upper trunk and proximal extremities.&#xD;
&#xD;
      Investigators hypothesize that the expression of immune-related genes are different between&#xD;
      small and large plaque psoriasis. The study of a genetically homogeneous cohort,&#xD;
      characterized by the relatively high prevalence of small plaque psoriasis in the Korean&#xD;
      population, may filter out spurious signals while allowing for significant associations to&#xD;
      emerge from a relatively low number of participants.&#xD;
&#xD;
      By comparing small and large plaque psoriasis, it is expected this study could lead to new&#xD;
      understandings of the mechanisms involved in spreading of psoriatic plaques and provide new&#xD;
      insights into psoriasis development.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Psoriasis is a common chronic skin disorder with an estimated prevalence in populations of&#xD;
      approximately 2%. Psoriatic skin lesions start with initial pinhead-sized macules and then&#xD;
      coalesce into plaques of varying sizes in diameter from one to several centimeters.&#xD;
&#xD;
      Despite the great strides in the studies for psoriasis, it is still unclear why psoriatic&#xD;
      skin lesions start with small macules and then spread peripherally. The occurrence of&#xD;
      psoriasis is thought to be the pathological consequence of an exaggerated immune response as&#xD;
      activated T cells, monocytes, neutrophils, and dendritic cells produce inflammatory cytokines&#xD;
      that drive the additional recruitment of inflammatory cells, further elaboration of&#xD;
      proinflammatory mediators, and the proliferation of keratinocytes. However, pathogenetic&#xD;
      mechanism for peripheral spreading of psoriasis needs to be further elucidated.&#xD;
&#xD;
      To study peripheral spreading of psoriasis, investigators plan to study &quot;small plaque&#xD;
      psoriasis&quot; and compare it to &quot;large plaque psoriasis&quot; in the Korean population.&#xD;
&#xD;
      Psoriasis vulgaris, so-called &quot;large plaque psoriasis&quot;, is the most common form of psoriasis,&#xD;
      seen in approximately 90% of all psoriasis patients. Red, scaly, symmetrically distributed&#xD;
      plaques are usually larger than 5 cm in diameter and characteristically localized to the&#xD;
      extensor aspects of the extremities, particularly the elbows and knees, along with scalp,&#xD;
      lower lumbosacral, buttocks, and genital involvement. Approximately 1/4 to 1/3 of large&#xD;
      plaque psoriasis participants have involvement of over 5% of their body surface area (BSA),&#xD;
      and disease of this extent is frequently painful and physically and/or socially debilitating&#xD;
      to a degree comparable with other chronic medical conditions.&#xD;
&#xD;
      On the other hand, &quot;small plaque psoriasis&quot; is the common or typical form of psoriasis that&#xD;
      occurs in adults particularly in Korea and other Asian countries. Korean small plaque&#xD;
      psoriasis, even when chronic, remain &lt;2 cm in size and widely distributed on upper trunk and&#xD;
      proximal extremities. Small plaque psoriasis is less severe than large plaque psoriasis, as&#xD;
      it usually responds to phototherapy and more potent therapies are rarely needed.&#xD;
&#xD;
      It is also noteworthy that there are well-known human leukocyte antigen (HLA) differences in&#xD;
      Caucasians in comparison with Asian participants with psoriasis, and a unique HLA haplotype&#xD;
      has been described in Korean participants with psoriasis. Furthermore, an allele of an&#xD;
      HLA-related gene, known as major histocompatibility complex I chain-related gene A, is known&#xD;
      as a susceptibility marker in Korean and Chinese participants with psoriasis, but not in&#xD;
      Spanish participants.&#xD;
&#xD;
      For a more comprehensive analysis of the difference between small and large plaque psoriasis,&#xD;
      investigators plan to compare these two different types of psoriasis only in the Korean&#xD;
      population. The study of a genetically homogeneous cohort, characterized by the relatively&#xD;
      high prevalence of small plaque psoriasis in the Korean population, may filter out spurious&#xD;
      signals while allowing for significant associations to emerge from a relatively low number of&#xD;
      participants. By comparing Korean psoriasis participants in two geographically separated&#xD;
      locations (Seoul, Korea vs. New York, NY, USA), it will also be interesting to understand the&#xD;
      interactions between genetics and the environment that are still not well defined.&#xD;
&#xD;
      It is anticipated this study could lead to new understanding of the mechanisms involved in&#xD;
      the spreading of psoriatic plaques and provide new insight into psoriasis pathogenesis.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Actual">June 2015</completion_date>
  <primary_completion_date type="Actual">June 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary outcome measure is the RT-PCR measurement of IL-17 in lesional psoriasis skin samples collected from patients in Korea.</measure>
    <time_frame>2 years</time_frame>
    <description>The primary outcome measure is the expression of IL-17 (the pivotal immune related molecule in psoriasis pathogenesis) in lesional psoriatic skin samples collected from patients in Korea. The expression of IL-17 is measured by Reverse transcription polymerase chain reaction (RT-PCR) and normalized to the expression of housekeeping gene (human acidic ribosomal protein [hARP]). The unit of outcome measure is log2(IL-17 expression/hARP expression).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The secondary outcome measure is the RT-PCR measurement of IL-17 in lesional psoriasis skin samples collected from patients at The Rockefeller Hospital, New York.</measure>
    <time_frame>2 years</time_frame>
    <description>The secondary outcome measure is the expression of IL-17 (the pivotal immune related molecule in psoriasis pathogenesis) in lesional psoriatic skin samples collected from patients at The Rockefeller Hospital, New York. The expression of IL-17 is measured by Reverse transcription polymerase chain reaction (RT-PCR) and normalized to the expression of housekeeping gene (human acidic ribosomal protein [hARP]). The unit of outcome measure is log2(IL-17 expression/hARP expression).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Psoriasis</condition>
  <arm_group>
    <arm_group_label>Biopsy and blood tests</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All subjects will undergo a skin biopsy and blood tests</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Skin biopsy and blood test</intervention_name>
    <description>Analysis of histology and gene expression in affected and unaffected skin</description>
    <arm_group_label>Biopsy and blood tests</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Self-identified as Korean (defined as being Korean and both parents are Korean)&#xD;
&#xD;
          -  History of small and/or large plaque psoriasis, for at least six months&#xD;
&#xD;
          -  At least 18 years of age&#xD;
&#xD;
          -  No treatment with topical steroids or vitamin D analogues for at least 2 weeks prior&#xD;
             to entering the study.&#xD;
&#xD;
          -  No treatment with systemic therapies, including phototherapy, acitretin, cyclosporine,&#xD;
             methotrexate and biologics 4 weeks prior to entering the study. Among biologics,&#xD;
             Ustekinumab (StelaraÂ®) requires a longer washout period of 12 weeks.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Erythrodermic, or pustular psoriasis as the sole or predominant form of psoriasis.&#xD;
&#xD;
          -  Photosensitizing illnesses such as lupus, polymorphous light eruption, or any disease&#xD;
             known to be worsened by UV light exposure.&#xD;
&#xD;
          -  History of malignant melanoma.&#xD;
&#xD;
          -  Pregnancy.&#xD;
&#xD;
          -  Immunocompromising diseases such as HIV infection.&#xD;
&#xD;
          -  Inflammatory diseases such as but not limited to Crohn's Disease, Multiple Sclerosis,&#xD;
             Rheumatoid Arthritis, Hashimoto's Disease.&#xD;
&#xD;
          -  Any medical, psychological or social condition that, in the opinion of the&#xD;
             Investigator, would jeopardize the health or well-being of the participant during any&#xD;
             study procedures or the integrity of the data. Participants taking medications that&#xD;
             induce photosensitivity may be included after careful review.&#xD;
&#xD;
          -  Poorly controlled medical conditions of any kind.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jaehwan Kim, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rockefeller Univesrity</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Rockefeller University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <study_first_submitted>August 6, 2013</study_first_submitted>
  <study_first_submitted_qc>August 8, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 12, 2013</study_first_posted>
  <last_update_submitted>May 5, 2016</last_update_submitted>
  <last_update_submitted_qc>May 5, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 6, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rockefeller University</investigator_affiliation>
    <investigator_full_name>Jaehwan Kim</investigator_full_name>
    <investigator_title>Clinical Scholar</investigator_title>
  </responsible_party>
  <keyword>Psoriasis</keyword>
  <keyword>Korean</keyword>
  <keyword>Healthy Volunteers</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

